Closure of a Prosthetic Mitral Valve Paravalvular Leak Using a Ventricular Septal Defect (VSD) Amplatzer Occluder Device

Background

Paravalvular leaks (PVL) are becoming more commonly experienced in clinical practice due to the increasing number of mitral valve replacements performed. There are about 182 000 valve replacements performed annually, with a 5–15% prevalence rate of paravalvular leaks [1]. About 1–5% of paravalvular leaks result in serious clinical consequences ranging from hemolytic anemia to congestive heart failure [2]. Due to increased mortality associated with surgical repair, percutaneous transcatheter closure procedures are increasingly being performed as an alternative to repeat surgery. We present the case of a 52-year-old woman who had a prosthetic mitral valve PVL successfully closed with a Ventricular septal defect (VSD) Amplatzer occluder device via an antegrade transseptal approach.

Case Report

PERCUTANEOUS TECHNIQUE:

The patient was placed under general anesthesia and surgical right internal jugular line for monitoring and medication administration. The TEE probe was inserted, and initial images were obtained. Right heart catheterization was then completed in the standard fashion. A transseptal puncture was also performed and a Baylis wire was inserted into the left atrium. After confirmation of left atrial pressure and waveform, the Baylis sheath was removed and an Agilis sheath was advanced into the left atrium. The dilator was removed, a multipurpose guiding catheter was then advanced through the Agilis and with TEE guidance, and a Glidewire was directed through the defect in the left ventricle. The guidewire was removed and an Amplatz extra-stiff wire was inserted. The guide was then removed and a 14-mm VSD occluder was advanced. The ventricular disc was deployed and withdrawn to sit within the perivalvular space (Figure 3). This demonstrated immediate reduction of 4+ mitral regurgitation to 2+ mitral regurgitation with significant improvement in hemodynamics (Table 1). TEE evaluation demonstrated that tissue capture around all rims was present and the device was subsequently released. The patient made good recovery and was discharged home a few days after the procedure. At follow-up, she reported no relapse of drug abuse.

Discussion

PVL results from inappropriate sealing between the structure of the implanted valve and the surrounding cardiac tissue, resulting in blood flow via the channel [3]. It occurs in about 5–15% of patients following prosthetic mitral valve replacement, with higher incidence following surgically implanted valves compared to percutaneously implanted ones, with the majority being crescent, oval, or round mitral PVLs [3]. Although rare, about 3% of these patients progress to heart failure, hemolytic anemia, or both, requiring prompt intervention [4]. As in our case, most patients present with signs of acute mitral regurgitation and heart failure. Our patient presented with acute mitral regurgitation resulting in congestive heart failure. The criterion standard for diagnosis is echocardiography, preferably transesophageal. Transthoracic echocardiography is not as sensitive and can underestimate the severity of the regurgitation due to the eccentricity of the mitral regurgitation jet, artifacts from the bioprosthesis, and technically challenging imaging. TEE also has more utility with increasing use of real-time 3D echocardiography to evaluate the bioprosthetic valve dysfunction and help guide the repair. Surgery has long been the criterion standard intervention strategy for repair of PVL, especially for patients with infectious endocarditis, concurrent need for bypass, or an unstable prosthesis [5,6]. However, percutaneous PVL repair has been gradually becoming more commonly used over the past decade, with large-volume centers creating tailored multidisciplinary teams and employing uniform approaches, significantly improving patient selection and timing to achieve optimal results [4]. A case series by Hernandez-Enriquez et al. suggests that even though there are similar results between percutaneous and surgical PVL closure in some series, PVL is a valid alternative to surgical correction because it is well tolerated [7]. Percutaneous valve closure is less invasive, permits multiple attempts, and is an option in patients who are at high risk for open heart surgery [8,9]. Another similar case report, by Abueletta et al., advocates that percutaneous PVL closure with VSD can be done at least 3 months after the prior surgery [10]. However, we believe it is best not to wait that long after surgery, and suggest prompt intervention because of worse clinical outcomes. Our patient’s case was reviewed by the heart valve team and, due to the worsening clinical condition, a decision was made to pursue percutaneous closure using the VSD occluder. Results for percutaneous PVL closure have been promising, with low complication rates, depending on the expertise of the interventionalist. As with any other type of surgical procedure, there is still an increased risk of endocarditis, even after the procedure, especially in patients with a history of drug abuse, like this patient. Percutaneous paravalvular leak repair has been shown to improve heart failure symptoms and to decrease hospitalizations and procedure-related adverse events [11,12]. More importantly, an advantage over surgery is the improved short and midterm survival rates in patients with no PVL to mild residual leak after the procedure [4].

Conclusions

Although the use of the Amplatzer VSD occluder device for this indication currently remains off-label, this article is in support of percutaneous closure devices in mitral PVL, even as the trend toward percutaneous cardiac interventions continues to increase.